Eton Pharmaceuticals Inc ETON.OQ ETON.O is expected to show a rise in quarterly revenue when it reports results on August 7 for the period ending June 30 2025
The Deer Park Illinois-based company is expected to report a 84.2% increase in revenue to $16.711 million from $9.07 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Eton Pharmaceuticals Inc is for a loss of 4 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Eton Pharmaceuticals Inc is $28.00, about 48.6% above its last closing price of $14.39
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | 0.06 | 0.05 | 0.07 | Beat | 31.3 |
Dec. 31 2025 | -0.01 | 0.00 | -0.02 | Missed | -500.6 |
Sep. 30 2024 | -0.01 | -0.01 | 0.03 | Beat | 400 |
Jun. 30 2024 | -0.07 | -0.07 | -0.12 | Missed | -71.4 |
Mar. 31 2024 | -0.07 | -0.04 | -0.03 | Beat | 33.3 |
Dec. 31 2023 | -0.04 | -0.04 | -0.09 | Missed | -125 |
Sep. 30 2023 | -0.10 | -0.10 | -0.02 | Beat | 80 |
Jun. 30 2023 | -0.09 | -0.09 | 0.15 | Beat | 266.7 |
This summary was machine generated August 5 at 20:55 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)